Indication
Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
7 clinical trials
6 products
6 drugs
Clinical trial
A Pilot Study of Pembrolizumab and Lenvatinib Combination Therapy in Patients With Previously Treated Advanced Gastroesophageal AdenocarcinomaStatus: Recruiting, Estimated PCD: 2025-12-30
Product
LenvatinibProduct
PembrolizumabClinical trial
A Phase I Pilot Study of Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab in Advanced Solid Tumors (PNeoVCA)Status: Recruiting, Estimated PCD: 2025-02-24
Drug
cyclophosphamideClinical trial
A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction CancerStatus: Active (not recruiting), Estimated PCD: 2024-10-31
Drug
AdavosertibProduct
Neoantigen Peptide VaccineClinical trial
Phase 2 Study of Avapritinib in Patients With CKIT or PDGFRA Mutation-Positive Malignant Solid TumorsStatus: Recruiting, Estimated PCD: 2025-02-03
Product
AvapritinibClinical trial
Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase 2 StudyStatus: Recruiting, Estimated PCD: 2024-07-31
Drug
TiragolumabProduct
RamucirumabProduct
Trifluridine and TipiracilClinical trial
A Pilot Trial of Pembrolizumab Plus Chemoradiotherapy in Participants With Unresectable Gastroesophageal CancerStatus: Active (not recruiting), Estimated PCD: 2024-07-18
Drug
DocetaxelDrug
5-FUDrug
mFOLFOX6Clinical trial
A Phase I Study of Intraperitoneal Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive CytologyStatus: Active (not recruiting), Estimated PCD: 2028-10-30